Study protocol for a multicentre randomised controlled trial: Safety, Tolerability, efficacy and quality of life Of a human recombinant alkaline Phosphatase in patients with sepsis-associated Acute Kidney Injury (STOP-AKI)

Esther Peters, Ravindra L Mehta, Patrick T Murray, Jürgen Hummel, Michael Joannidis, John A Kellum, Jacques Arend, Peter Pickkers, Esther Peters, Ravindra L Mehta, Patrick T Murray, Jürgen Hummel, Michael Joannidis, John A Kellum, Jacques Arend, Peter Pickkers

Abstract

Introduction: Acute kidney injury (AKI) occurs in 55-60% of critically ill patients, and sepsis is the most common underlying cause. No pharmacological treatment options are licensed to treat sepsis-associated AKI (SA-AKI); only supportive renal replacement therapy (RRT) is available. One of the limited number of candidate compounds in clinical development to treat SA-AKI is alkaline phosphatase (AP). The renal protective effect of purified bovine intestinal AP has been demonstrated in critically ill sepsis patients. To build on these observations, a human recombinant AP (recAP) was developed, of which safety and efficacy in patients with SA-AKI will be investigated in this trial.

Methods: This is a randomised, double-blind, placebo-controlled, 4-arm, proof-of-concept, dose-finding adaptive phase IIa/IIb study, conducted in critically ill patients with SA-AKI. A minimum of 290 patients will be enrolled at ∼50 sites in the European Union and North America. The study involves 2 parts. Patients enrolled during Part 1 will be randomly assigned to receive either placebo (n=30) or 1 of 3 different doses of recAP (n=30 per group) once daily for 3 days (0.4, 0.8 or 1.6 mg/kg). In Part 2, patients will be randomly assigned to receive the most efficacious dose of recAP (n=85), selected during an interim analysis, or placebo (n=85). Treatment must be administered within 24 hours after SA-AKI is first diagnosed and within 96 hours from first diagnosis of sepsis. The primary end point is the area under the time-corrected endogenous creatinine clearance curve from days 1 to 7. The key secondary end point is RRT incidence during days 1-28.

Ethics and dissemination: This study is approved by the relevant institutional review boards/independent ethics committees and is conducted in accordance with the ethical principles of the Declaration of Helsinki, guidelines of Good Clinical Practice, Code of Federal Regulations and all other applicable regulations. Results of this study will reveal the efficacy of recAP for the improvement of renal function in critically ill patients with SA-AKI and will be published in a peer-reviewed scientific journal.

Trial registration number: NCT02182440; Pre-results.

Keywords: acute kidney injury; alkaline phosphatase; randomized controlled trial; sepsis; therapy.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Trial flow. ICF, informed consent form; recAP, human recombinant alkaline phosphatase; RRT, renal replacement therapy; SA-AKI, sepsis-associated acute kidney injury; h, hours.
Figure 2
Figure 2
Timeline. IV, intravenous; SA-AKI, sepsis-associated acute kidney injury; h, hours.

References

    1. Hoste EA, Bagshaw SM, Bellomo R et al. . Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med 2015;41:1411–23. 10.1007/s00134-015-3934-7
    1. Lameire NH, Bagga A, Cruz D et al. . Acute kidney injury: an increasing global concern. Lancet 2013;382:170–9. 10.1016/S0140-6736(13)60647-9
    1. Case J, Khan S, Khalid R et al. . Epidemiology of acute kidney injury in the intensive care unit. Crit Care Res Pract 2013;2013:479730 10.1155/2013/479730
    1. Martin GS, Mannino DM, Eaton S et al. . The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546–54. 10.1056/NEJMoa022139
    1. Peters E, Heemskerk S, Masereeuw R et al. . Alkaline phosphatase: a possible treatment for sepsis-associated acute kidney injury in critically ill patients. Am J Kidney Dis 2014;63:1038–48. 10.1053/j.ajkd.2013.11.027
    1. Bentala H, Verweij WR, Huizinga-Van der Vlag A et al. . Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock 2002;18:561–6. 10.1097/00024382-200212000-00013
    1. Koyama I, Matsunaga T, Harada T et al. . Alkaline phosphatases reduce toxicity of lipopolysaccharides in vivo and in vitro through dephosphorylation. Clin Biochem 2002;35:455–61. 10.1016/S0009-9120(02)00330-2
    1. Picher M, Burch LH, Hirsh AJ et al. . Ecto 5′-nucleotidase and nonspecific alkaline phosphatase. Two AMP-hydrolyzing ectoenzymes with distinct roles in human airways. J Biol Chem 2003;278:13468–79. 10.1074/jbc.M300569200
    1. Millán JL. Alkaline phosphatases: structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes. Purinergic Signal 2006;2:335–41. 10.1007/s11302-005-5435-6
    1. Pickkers P, Snellen F, Rogiers P et al. . Clinical pharmacology of exogenously administered alkaline phosphatase. Eur J Clin Pharmacol 2009;65:393–402. 10.1007/s00228-008-0591-6
    1. Heemskerk S, Masereeuw R, Moesker O et al. . Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med 2009;37:417–23.e1. 10.1097/CCM.0b013e31819598af
    1. Pickkers P, Heemskerk S, Schouten J et al. . Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care 2012;16:R14 10.1186/cc11159
    1. Kiffer-Moreira T, Sheen CR, Gasque KC et al. . Catalytic signature of a heat-stable, chimeric human alkaline phosphatase with therapeutic potential. PLoS ONE 2014;9:e89374 10.1371/journal.pone.0089374
    1. Peters E, Geraci S, Heemskerk S et al. . Alkaline phosphatase protects against renal inflammation through dephosphorylation of lipopolysaccharide and adenosine triphosphate. Br J Pharmacol 2015;172:4932–45. 10.1111/bph.13261
    1. Peters E, Heuberger JA, Tiessen R et al. . Pharmacokinetic modeling and dose selection in a randomized, double-blind, placebo-controlled trial of a human recombinant alkaline phosphatase in healthy volunteers. Clin Pharmacokinet 2016;55:1227–37 10.1007/s40262-016-0399-y
    1. Dellinger RP, Levy MM, Rhodes A et al. . Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580–637. 10.1097/CCM.0b013e31827e83af
    1. Group KDIGOKAKIW. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;2:1–138. 10.1038/kisup.2012.1
    1. Chan AW, Tetzlaff JM, Gøtzsche PC et al. . SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586 10.1136/bmj.e7586
    1. Bone RC, Balk RA, Cerra FB et al. . Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644–55. 10.1378/chest.101.6.1644
    1. Pickering JW, Frampton CM, Walker RJ et al. . Four hour creatinine clearance is better than plasma creatinine for monitoring renal function in critically ill patients. Crit Care 2012;16:R107 10.1186/cc11391
    1. Baumann TJ, Staddon JE, Horst HM et al. . Minimum urine collection periods for accurate determination of creatinine clearance in critically ill patients. Clin Pharm 1987;6:393–8.
    1. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet 2012;380:756–66. 10.1016/S0140-6736(11)61454-2
    1. Palevsky PM, Zhang JH, O'Connor TZ et al. , Network VNARFT. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008;359:7–20. 10.1056/NEJMoa0802639
    1. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994;50:1029–41. 10.2307/2533441
    1. Bellomo R, Chapman M, Finfer S et al. . Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000;356:2139–43. 10.1016/S0140-6736(00)03495-4
    1. Janssen van Doorn K, Spapen H, Geers C et al. . Sepsis-related acute kidney injury: a protective effect of drotrecogin alpha (activated) treatment? Acta Anaesthesiol Scand 2008;52: 1259–64. 10.1111/j.1399-6576.2008.01738.x
    1. Zhang P, Yang Y, Lv R et al. . Effect of the intensity of continuous renal replacement therapy in patients with sepsis and acute kidney injury: a single-center randomized clinical trial. Nephrol Dial Transplant 2012;27:967–73. 10.1093/ndt/gfr486
    1. Cohen J. The immunopathogenesis of sepsis. Nature 2002;420:885–91. 10.1038/nature01326
    1. Good DW, George T, Watts BA III. Lipopolysaccharide directly alters renal tubule transport through distinct TLR4-dependent pathways in basolateral and apical membranes. Am J Physiol Renal Physiol 2009;297:F866–74. 10.1152/ajprenal.00335.2009
    1. Singer M, Deutschman CS, Seymour CW et al. . The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315:801–10. 10.1001/jama.2016.0287

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa